TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06632457: A Phase III Double-blind, Randomised, Placebo-controlled Trial to Evaluate Liver-related Clinical Outcomes and Safety of Once Weekly Injected Survodutide in Participants With Compensated Non-alcoholic Steatohepatitis/Met

Sponsor: Boehringer Ingelheim · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 1590 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$565,728

Rescue Site Savings

+$377,152

Unlock Full NCT06632457 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06632457 Rescue Dossier →